Roche provides molecular testing solutions to differentiate Covid variants
March 16th, 2022 Roche and its subsidiary Tib Molbiol have announced that the companies have tests that identify the SARS-CoV-2 (Covid-19, or coronavirus) subvarients including Delta, Omicron, and B.A. 1.0 – B.A. 3.0. Use of these tests assess the spread of circulating variants, and can help monitor the efficacy of coronavirus countermeasures adopted worldwide. Roche Diagnostics CEO Thomas Schinecker has highlighted the importance of the product, stating, “It's critical to quickly and accurately identify variants to inform ongoing research - including the ongoing development of therapeutics and vaccines. This can potentially stop or slow down the advancement of the disease.”
Product InnovationIn response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.
Lorem Ipsum text header Report Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.
Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.